Amgens Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
CGEM Stock | USD 12.18 0.02 0.16% |
About 62% of Cullinan Oncology's investor base is looking to short. The analysis of the overall investor sentiment regarding Cullinan Oncology LLC suggests that many traders are alarmed. Cullinan Oncology's investing sentiment overview a quick insight into current market opportunities from investing in Cullinan Oncology LLC. Many technical investors use Cullinan Oncology LLC stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Cullinan |
In an investor update on Tuesday, Amgen Inc released data from Phase 3 trials of rocatinlimab and Uplizna . HORIZON Phase 3 trial evaluated rocatinlimab for atopic dermatitis in 726 patients. Amgen reported that rocatinlimab outperformed a placebo regarding the severity and extent of the disease. 32.8 percent of rocatinlimab-treated subjects achieved an EASI-75 response at week 24 vs. 13.7 percent placebo. 19.3 percent of rocatinlimab-treated subjects achieved a vIGA-AD 01 respo
Read at finance.yahoo.com
Cullinan Oncology Fundamental Analysis
We analyze Cullinan Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cullinan Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cullinan Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Cullinan Oncology is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Cullinan Oncology LLC Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cullinan Oncology stock to make a market-neutral strategy. Peer analysis of Cullinan Oncology could also be used in its relative valuation, which is a method of valuing Cullinan Oncology by comparing valuation metrics with similar companies.
Peers
Cullinan Oncology Related Equities
ACET | Adicet Bio | 6.67 | ||||
AUTL | Autolus Therapeutics | 6.33 | ||||
OLMA | Olema Pharmaceuticals | 3.92 | ||||
ZNTL | Zentalis Pharmaceuticals | 3.77 | ||||
LYEL | Lyell Immunopharma | 3.23 | ||||
RVMD | Revolution Medicines | 1.32 | ||||
SANA | Sana Biotechnology | 1.24 | ||||
IPSC | Century Therapeutics | 1.00 | ||||
DAWN | Day One | 0.72 | ||||
CCCC | C4 Therapeutics | 1.10 | ||||
GLUE | Monte Rosa | 1.14 | ||||
EWTX | Edgewise Therapeutics | 1.33 | ||||
MLYS | Mineralys Therapeutics, | 1.68 | ||||
LYRA | Lyra Therapeutics | 4.55 | ||||
BOLT | Bolt Biotherapeutics | 5.26 | ||||
VOR | Vor Biopharma | 6.72 |
Check out Cullinan Oncology Hype Analysis, Cullinan Oncology Correlation and Cullinan Oncology Performance. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.